Patients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of this infection. Despite the successes achieved in the fight against HBV, the virus cannot be completely defeated due to the presence of hidden forms of the disease, escaping the field of vision of a rheumatologist and an infectionist. Based on the results of the analysis of current publications, the paper presents the rationale for a complete immunological screening of patients with rheumatic diseases when prescribing antirheumatic therapy. The issues of the role of COVID-19 in the exacerbation of chronic viral hepatitis B, antiviral prevention and monitoring are discussed, the classification of antirheumatic drugs according to the risk of HBV reactivation is presented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.26442/00403660.2024.05.202707 | DOI Listing |
Rheumatol Int
January 2025
Department of Rheumatology, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
This systematic review aims to summarise the association between skin disease and quality of life (QoL) in people with psoriatic arthritis (PsA) and identify areas for future research and management. This review was registered on PROSPERO (CRD42024500994). Databases were searched for articles in English published until 7th January 2025.
View Article and Find Full Text PDFBull World Health Organ
February 2025
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.
Objective: To evaluate the adoption, effectiveness and cost-effectiveness of digital health interventions for rheumatic disease management.
Methods: Between 25 May 2024 and 2 June 2024, we systematically searched PubMed®, Scopus, ClinicalTrials.gov, the Global Observatory for eHealth and the World Bank Open Knowledge Repository for randomized controlled trials (RCTs) evaluating digital health interventions for rheumatic disease management.
Rev Med Suisse
January 2025
Service de rhumatologie, HFR Fribourg, 1708 Fribourg.
In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price.
View Article and Find Full Text PDFBackground And Purpose: The introduction and development of new total knee arthroplasty (TKA) implant designs are industry driven. To date, an adequately powered randomized controlled trial (RCT) to provide evidence of the superiority of novel implant designs over conventional ones is often lacking. The aim of our RCT was to investigate the functional outcomes of a novel TKA implant design compared with 2 conventional TKA designs.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Medical Imaging, Lille Catholic University, Saint-Philibert Hospital, ETHICS laboratory, Lille, EA, France.
Objective: The objective of this study was to explore the ability of dual-energy computed tomography (DECT) to detect monosodium urate (MSU) crystal deposits in the kidneys and renal artery walls, and uric acid urolithiasis, in patients with gout and chronic kidney disease (CKD).
Methods: Patients with gout and with stage 2-4 CKD were prospectively included in this cross-sectional study. Patients underwent renal, knee and feet DECT scans.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!